Evaluation of efficacy and safety of PARP inhibitors in breast cancer: A systematic review and meta-analysis.

ABSTRACT:

Background

Many breast cancer clinical trials with PARPi have been completed or are currently carried out, either by monotherapy or combined with chemotherapy. We aim to assess the efficacy and safety of PARPi in breast cancer patients as compared to chemotherapy.

Methods

A comprehensive literature search of PubMed, EMBASE, CENTRAL, conference meetings and clinical trial registry was performed. The primary outcomes were progression-free survival (PFS), overall survival (OS), overall response rate (ORR). The secondary outcome was safety profile. The comparative effects were measured using hazard ratio (HR) or relative risk (RR) with 95% confidence interval. Subgroup analyses were conducted based on types of intervention and baseline characteristics of patients.

Results

SUBMITTER: Chang XF 

PROVIDER: S-EPMC8215282 | biostudies-literature | 2021 Oct

REPOSITORIES: biostudies-literature